What Arinac Treats: Main Uses and Benefits

This combination product is indicated for the short-term symptomatic relief of acute viral illnesses. This medication is commonly used for the symptomatic management of conditions associated with acute or disruptive episodes, such as the common cold and influenza.

Managing Co-Occurring Cold and Flu Symptoms

This medication is applied when patients require assistance in addressing symptoms related to systemic imbalance, including headache, body aches, and fever, alongside symptoms that interfere with daily functioning due to nasal obstruction. The therapeutic benefit supports the easing of the overall symptom burden of these combined manifestations during periods of heightened symptoms.

Targeted Relief for Nasal and Sinus Congestion

This medication is commonly used across conditions presenting with acute episodes marked by the discomfort of upper airway obstruction and pressure. It is specifically applied in addressing symptoms that create noticeable functional strain, such as a stuffy nose, blocked nasal passages, and associated sinus discomfort. The product provides symptomatic relief that may assist with addressing upper airway obstruction, helping to ease distress and supporting day-to-day comfort when symptoms are more noticeable.

---

Key Use: Relief for Co-occurring Pain and Congestion

---

Regulatory References

1. National Institutes of Health (NIH) DailyMed

Who Can and Cannot Use Arinac?

This section defines the official population eligibility rules for the Ibuprofen/Pseudoephedrine combination product, strictly based on regulatory prescribing information from authorities such as the FDA and EMA.

---

Approved Age Groups and Limitations

Age Group	Official Eligibility Status
Adults (>18 years)	Approved (Primary use group)
Adolescents (12-17 years)	Approved
Children (<12 years)	Not Recommended/Contraindicated (Safety/Efficacy Not Established)

Use in older adults requires caution due to an increased risk of serious reactions, including gastrointestinal bleeding and renal impairment.

---

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for individuals with the following conditions, primarily due to the active ingredients (NSAID and Sympathomimetic):

• Hypersensitivity or NSAID-Induced Allergy (e.g., asthma, angioedema) to Ibuprofen, Pseudoephedrine, or Aspirin.
• Severe Organ Impairment: Severe renal failure, hepatic failure, or severe heart failure.
• Cardiovascular Disease: Severe or uncontrolled hypertension or coronary artery disease.
• Gastrointestinal History: Active or recurrent peptic ulcer or hemorrhage.
• Other Conditions: Narrow-angle glaucoma, pheochromocytoma, or concurrent use with MAOIs (Monoamine Oxidase Inhibitors) or within 14 days of stopping them.
• Pregnancy Status: Contraindicated in the third trimester of pregnancy and not recommended during the first and second trimesters or while breastfeeding.

This combination product has officially documented interaction restrictions related to both its Ibuprofen and Pseudoephedrine components. The Pseudoephedrine component results in a contraindication for co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid, Phenelzine, and Linezolid. Due to the risk of severe hypertensive crisis, a mandatory 14-day separation period is required after stopping an MAOI before this product can be taken.

The Ibuprofen component requires avoiding combination with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to prevent an additive risk of gastrointestinal bleeding. The risk of bleeding and hemorrhagic events is formally documented to increase when this medication is combined with anticoagulants (such as Warfarin), antiplatelet agents, corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs).

Additionally, the regulatory label notes that Ibuprofen may alter the exposure of certain medicines, potentially increasing the plasma concentration of Lithium and Methotrexate. It may also reduce the antihypertensive effect of agents like ACE inhibitors and Diuretics. Consumption of alcohol is explicitly constrained due to an increased chance of severe stomach bleeding. A population-specific caution notes that the risk of severe gastrointestinal bleeding is heightened in elderly patients aged 60 or older.

Inhibition of Prostaglandin Synthesis

This mechanism modulates the systemic, biochemical component of the inflammatory response through the Ibuprofen molecule. It functions by inhibiting Cyclooxygenase (COX-1 and COX-2) enzymes , which are critical for converting arachidonic acid into mediators such as prostaglandins. The resulting reduction of prostaglandin synthesis, particularly PGE2 in the hypothalamus, lowers an elevated body temperature set-point and reduces the functional sensitization of peripheral nociceptors.

---

alpha-Adrenergic Receptor-Mediated Vasoconstriction

This mechanism is focused on altering localized, structural physiology through the Pseudoephedrine component. The molecule acts as an agonist on Alpha-1 Adrenergic Receptors (alpha1) in the smooth muscle of the nasal and sinus lining. This alpha1 agonism triggers localized vasoconstriction, physically narrowing the arterioles and venules. This physiological adjustment reduces blood flow and fluid volume within the mucosal tissue, which functionally reduces mucosal swelling.

---

Mechanistic Synergy

The drug's overall physiological action is shaped by the complementary action of these two distinct mechanisms. Ibuprofen modulates the humoral cascade for systemic modulation (inflammation, thermoregulation), while Pseudoephedrine modulates vascular tone via the autonomic nervous system for localized structural change (mucosal vascular volume reduction).

Administration Instructions

Arinac (ibuprofen and pseudoephedrine hydrochloride) is an oral medication that is used according to specific administration guidelines to ensure correct dosing and administration.

Administration Scope	Detail
Route of Administration	Oral. Swallow the tablet or caplet whole.
Dosing Schedule (Adults/Children 12)	The standard dose is 1 tablet (200 mg ibuprofen / 30 mg pseudoephedrine HCl). If symptoms are not relieved by one dose, a second tablet may be used.
Frequency and Maximum Dose	Take one dose every 4 to 6 hours as needed. Do not exceed a maximum of 6 tablets in any 24-hour period unless directed by a healthcare professional.
Timing in Relation to Meals	Take the medicine with food or milk if stomach upset occurs.
Age-Group Rules	This product is not for use in children under 12 years of age.

Procedural Guidance

The administration of this medicine follows the principle of using the lowest effective dose for the shortest duration necessary. This principle guides the usage protocol.

Step Sequence:

1. Swallow the recommended dose of 1 or 2 tablets whole, preferably with a glass of water.
2. Administer the dose after a meal or with milk if stomach upset is a concern.
3. Repeat the dose every 4 to 6 hours as required, ensuring the time between doses is adequate.
4. Strictly adhere to the maximum limit of 6 tablets within a 24-hour period to prevent overdose.

Research evidence / Overview of studies for Arinac

Evidence from Clinical Trials on Cold and Flu Symptoms

The research landscape includes short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time when conditions involve periods of heightened symptoms, such as the common cold or influenza. In these trials, research examined adults and adolescents (typically age 12 and older) presenting with co-occurring outcomes linked to inflammatory or irritative states, pain, and congestion. Research examined outcomes related to physical discomfort, such as headache and body aches, and outcomes related to systemic or functional imbalance, like a sore throat. At the same time, studies monitored outcomes reflecting daily functioning or activity level, specifically those related to nasal and sinus congestion. Findings describe patterns observed in the studies that compared the product containing both ingredients to an inactive substance (placebo). The available evidence provides insight into how symptoms evolved in the observed populations during periods of increased symptom activity.

---

️ Comparison with Placebo and Single-Ingredient Formulations

Research explored how the fixed-dose combination compared to either an inactive placebo or to one of the two active ingredients taken alone (monotherapy). Studies were conducted during periods of increased symptom activity to understand the contribution of each component to the overall symptomatic profile. Research highlights changes measured during the study period for both pain-related and congestion-related outcomes. Findings indicate that the combination showed different patterns compared to the placebo, and separate data describe patterns related to the Ibuprofen component and the Pseudoephedrine component within their respective symptom axes. However, comparative evidence is lacking in some research areas, particularly detailed long-term head-to-head trials against taking the two single components at the same time.

---

️ Duration of Evidence and Long-Term Follow-up

Studies exploring short-term symptom changes typically monitored responses over defined time intervals that rarely exceeded three to seven days. This short duration reflects the typical course of the conditions being studied—conditions associated with acute or disruptive episodes like the common cold. As a result, follow-up durations were limited in the primary studies. Long-term effects remain to be fully established, and there is limited information for long-term outcomes, such as durability of response or patterns of chronic use. Research provides context but not individual predictions about symptom evolution beyond this initial short treatment period.

---

What Research Gaps and Uncertainties Exist

While the available evidence contributes to the broader evidence landscape for short-term symptom management, certain aspects are not fully established. Comparative evidence is lacking for a definitive, broad-scale assessment of the fixed-dose combination versus simply co-administering the single-ingredient products. Furthermore, the short-term focus means that long-term effects remains to be fully established, and research is ongoing in certain areas. Evidence quality varies across studies, and some subgroup findings are uncertain due to modest sample sizes in specific populations. Research provides context but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Evidence highlights what is known and what is still uncertain regarding the management of conditions characterized by fluctuating or episodic manifestations.

Key Studies & References

1. Label: IBUPROFEN AND PSEUDOEPHEDRINE HCL capsule, liquid filled (DailyMed - FDA)
2. Ibuprofen + Pseudoephedrine Caplets (Health Canada Product Monograph)

Common questions about Arinac (FAQ)

---

Q: What is Arinac used to treat?

Arinac is indicated for the temporary relief of pain associated with common symptoms such as sore throat, fever, the common cold, and upper respiratory tract infections. According to the official product information, the medication is used to alleviate these specific discomforts.

Q: Can I take Arinac if I am also taking other NSAIDs?

Regulatory documents state that using Arinac concurrently with other non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin is not recommended. This includes low-dose aspirin regimens sometimes used for heart protection, as combining these medications may increase the risk of certain side effects.

Q: Does Arinac contain ingredients that could affect sleep?

Official information indicates that Arinac contains Pseudoephedrine Hydrochloride, which is classified as a sympathomimetic amine. This type of ingredient can potentially cause central nervous system effects such as nervousness or insomnia in some people. Patients are advised to note that taking it close to bedtime may increase the risk of sleep interference.

Q: Is Arinac suitable for long-term use?

Regulatory documents recommend that Arinac be used for short-term treatment only. If the patient's symptoms persist or worsen after 3 days of use, official guidelines recommend that use of the medicine be discontinued.

Q: What are the active ingredients in Arinac?

Arinac contains two primary active ingredients: Ibuprofen and Pseudoephedrine Hydrochloride. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to help with pain and fever, while Pseudoephedrine acts as a decongestant to relieve nasal stuffiness.

Q: Can I drink alcohol while taking Arinac?

According to the official product information, regulatory sources advise against the concurrent use of Arinac and alcohol. The combination may increase the risk of certain side effects, particularly affecting the gastrointestinal tract.

Q: Should Arinac be taken with food?

Official guidance indicates that Arinac may be taken with food, a glass of water, or milk. This recommendation is typically included in the product information to help minimize potential gastrointestinal discomfort.

The official regulatory documents specify mandatory conditions for the storage and disposal of Arinac (Ibuprofen and Pseudoephedrine) tablets.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C. The product must be protected from excess moisture and heat. It must be kept in its original container with the lid tightly closed and should not be frozen or refrigerated. A mandatory safety requirement is to keep all medication out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused medication should be discarded using a community drug take-back program as the preferred method. If a take-back program is unavailable, the tablets must be mixed with an undesirable substance, sealed in a container, and disposed of in the household trash. The labeling does not recommend flushing the product down the toilet or sink.